Cartesian Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Cartesian Therapeutics

02/05/2025 14:05

Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Frederick Maryland-based  company is expected to report a 86.5% decrease in revenue to $785.71 thousand from $5.84 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 71 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $40.50​, above​ its last closing price of $12.27. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.87
-0.80
-0.59
Beat
26.3
Sep. 30 2024
-0.78
-0.79
-1.13
Missed
-42.7
Jun. 30 2024
-0.91
-1.07
0.54
Beat
150.6​
Mar. 31 2024
-0.80
-0.88
-10.50
Missed
-1,086.4
​​Dec. 31 2023
-0.60
-1.05
-2.10
Missed
-100
Sep. 30 2023
-1.34
-1.75
-1.80
Missed
-2.9​
Jun. 30 2023
-2.31
-2.40
-2.10
Beat
12.5
Mar. 31 2023
-2.62
-2.61
-4.20
Missed
-60.7

This summary was machine generated May 2 at 13:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)